Department of Clinical Neurological Sciences, London Health Science Center, University of Western Ontario (Western University, London, ON, Canada.
Eur J Neurol. 2021 Apr;28(4):1396-1400. doi: 10.1111/ene.14633. Epub 2020 Dec 5.
Blood pressure (BP) changes during alemtuzumab infusions are poorly understood. The aim of this study was to examine BP changes during alemtuzumab infusions in persons with multiple sclerosis (PwMS).
This was a retrospective cohort review of systolic (S) and diastolic (D) BP in PwMS receiving alemtuzumab.
Thirty-one patients were identified; 22 (64.5%) were women. Mean age and disease duration were 35.2 ± 7.1 and 9.2 ± 5.4 years, respectively. There was no history of hypertension or vascular events. Mean baseline SBP was 119.8 ± 15.1 mmHg, 118.8 ± 14.3 mmHg and 106.5 ± 6.1 mmHg whilst mean DBP was 75.3 ± 9.2 mmHg, 74.1 ± 12.4 mmHg and 69.2 ± 4.3 mmHg at doses 1, 6 and 9, respectively. During the first cycle, SBP increased by 19.2 ± 9.4 mmHg, with comparable percentage increases over the five infusions (16%, 22%, 17%, 11%, 13%, respectively). DBP increased by 6.2 ± 3.8 mmHg with similar percentage increases over the five infusions (8.4%, 11.5%, 5.5%, 7%, 3%). For the second cycle, SBP increased by 16.9 ± 3.2 mmHg, with similar increases over the 3 days (12%, 15%, 17%). DBP increased by 5.4 ± 4.2 mmHg (11%, 9%, 12.8%). The third cycle demonstrated increased mean and percentage of SBP and DBP by 8.9 ± 2.3 mmHg (10%, 70%, 11.8%) and 4.2 ± 1.9 mmHg (3%, 2%, 6.5%), respectively. Collectively, for 31 patients, in the first cycle, mean SBP increased from 119.8 ± 15.1 mmHg to 138.8 ± 13 mmHg (p ˂ 0.001), whilst mean DBP increased from 74.5 ± 9.2 mmHg to 79.2 ± 9.1 mmHg (p = 0.007). Overall, 17 (54.8%) patients had increasing BP by ≥20% and nine (29%) had increasing BP by ≥20 mmHg from baseline.
This demonstrates significant increases in BP during alemtuzumab infusions in PwMS.
尚不清楚阿仑单抗输注期间血压（BP）的变化情况。本研究旨在观察多发性硬化症（MS）患者接受阿仑单抗输注期间的 BP 变化。
这是一项回顾性队列研究，评估了接受阿仑单抗治疗的 MS 患者的收缩压（SBP）和舒张压（DBP）变化情况。
共确定了 31 例患者；22 例（64.5%）为女性。平均年龄和病程分别为 35.2±7.1 岁和 9.2±5.4 年。无高血压或血管事件病史。基线时 SBP 分别为 119.8±15.1mmHg、118.8±14.3mmHg 和 106.5±6.1mmHg，DBP 分别为 75.3±9.2mmHg、74.1±12.4mmHg 和 69.2±4.3mmHg，剂量分别为 1、6 和 9。在第一个周期中，SBP 升高了 19.2±9.4mmHg，五个输注周期中 SBP 的百分比增加相似（分别为 16%、22%、17%、11%、13%）。DBP 升高了 6.2±3.8mmHg，五个输注周期中 DBP 的百分比增加相似（分别为 8.4%、11.5%、5.5%、7%、3%）。在第二个周期中，SBP 升高了 16.9±3.2mmHg，3 天内的增加幅度相似（分别为 12%、15%、17%）。DBP 升高了 5.4±4.2mmHg（分别为 11%、9%、12.8%）。第三个周期的 SBP 和 DBP 的平均和百分比增加分别为 8.9±2.3mmHg（10%、70%、11.8%）和 4.2±1.9mmHg（3%、2%、6.5%）。总体而言，31 例患者的 SBP 从基线时的 119.8±15.1mmHg 增加至 138.8±13mmHg（p<0.001），DBP 从 74.5±9.2mmHg 增加至 79.2±9.1mmHg（p=0.007）。总体而言，17 例（54.8%）患者的 BP 升高≥20%，9 例（29%）患者的 BP 升高≥20mmHg 基线值。
本研究表明，阿仑单抗输注期间 MS 患者的 BP 显著升高。
